Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHOD FOR THE PREPARATION OF ENTEROLACTONE FROM MATAIRESINOL
Document Type and Number:
WIPO Patent Application WO/2003/066616
Kind Code:
A1
Abstract:
This invention concerns a method for the preparation of enterolactone. The method is characterized by the steps of a) transforming the phenolic hydroxyl groups of matairesinol to groups R, which are removable by hydrogenolysis, to give Compound B in Scheme 1,b) substituting the groups R in Compound B in Scheme 1 with hydrogen to give bis-3,3'-O-methylenterolactone (Compound C), andc) converting the methoxy groups in bis-3,3'-O-methylenterolactone to hydroxyl groups to give enterolactone. This invention concerns also a new group of compounds having the formula of Compound B in Scheme 1.

Inventors:
SJOEHOLM RAINER (FI)
EKLUND PATRIK (FI)
LINDHOLM ANNA (SE)
Application Number:
PCT/FI2003/000043
Publication Date:
August 14, 2003
Filing Date:
January 21, 2003
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HORMOS NUTRACEUTICAL OY LTD (FI)
SJOEHOLM RAINER (FI)
EKLUND PATRIK (FI)
LINDHOLM ANNA (SE)
International Classes:
A23L33/105; C07C69/017; C07D307/12; C07D307/33; C07D307/92; C07D493/04; (IPC1-7): C07D307/33; A61K31/34
Domestic Patent References:
WO1997014670A11997-04-24
Other References:
EKLUND PATRIK ET AL.: "Synthesis of (-)-matairesinol, (-)-enterolactone and (-)-enterodiol from the natural lignan hydroxymatairesinol", ORGANIC LETTERS, vol. 5, no. 4, 2003, pages 491 - 493, XP002964968
MAKELA TARU H. ET AL.: "Synthesis of enterolactone and enterodiol precursors as potential inhibitors of human estrogen synthetase (aromatase)", STEROIDS, vol. 65, 2000, pages 437 - 441, XP004215771
SIBI MUKUND P. ET AL.: "Free-radical-mediated conjugate additions. Enantioselective synthesis of butyrolactone natural products: (-). Enterolactone, (-)-arctigenin, (-)-isoarctigenin, (-)-nephrosteranic acid and (-)-roccellaric acid", J. ORG. CHEM., vol. 67, 2002, pages 1738 - 1745, XP002964969
TOMOYA OKUNISHI ET AL.: "Enantiomeric compositions and biosynthesis of wikstroemia sikokiana lignans", J. WOOD SCI., vol. 46, 2000, pages 234 - 242, XP002959077
FUMIO KAWAMURA ET AL.: "Photodiscoloration of western hemlock (tsuga heterophylla) sapwood III early stage of photodiscoloration reaction with lignans", J. WOOD SCI., vol. 44, 1998, pages 47 - 55, XP002964970
Attorney, Agent or Firm:
Öhman, Ann-marie c/o Hormos Medical Corporation (Itäinen Pitkäkatu 4 B, Turku, FI)
Download PDF:
Claims:
CLAIMS
1. Method for the preparation of enterolactone from matairesinol, characterized by the steps of a) transforming the phenolic hydroxyl groups of matairesinol to groups R, which are removable by hydrogenolysis, to give Compound B in Scheme 1, b) substituting the groups R in Compound B in Scheme 1 with hydrogen, to give bis3, 3'Omethylenterolactone, and c) converting the methoxy groups in bis3, 3'Omethylenterolactone to hydroxyl groups to give enterolactone.
2. The method according to claim 1, characterized in that the phenolic hydroxyl groups of matairesinol are transformed to such Rgroups, which define the Compound B in Scheme 1 as an ester, ether, sulfonyl ester, O arylisourea, aryl cyanate, aryloxytetrazole or arylbenzoxazole.
3. The method according to claim 2, characterized in that the transformation step is carried out by use of an anhydride or halide of a carboxylic acid, phosphoric acid, or sulfonic acid; a carbodiimide; cyanogen bromide; a chlorotetrazole or a chlorobenzoxazole.
4. The method according to claim 3, characterized in that the transformation step is carried out by use of a sulfonic acid anhydride.
5. The method according to claim 4, characterized in that the sulfonic acid anhydride is triflic acid anhydride.
6. The method according to any of the foregoing claims, characterized in that the substitution of the groups R in Compound B in Scheme 1 with hydrogen atoms is carried out by catalytic hydrogen transfer using a hydrogen donor and catalyst which is a palladium or Ni complex, palladium metal on a carrier such as carbon, platinum oxide or a Raneytype catalyst such as RaneyNi.
7. The method according to any of the claims 15, characterized in that the substitution of the groups R in Compound B in Scheme 1 with hydrogen atoms is carried out by catalytic hydrogenation.
8. The method according to claim 6 or 7, characterized in that the substitution reaction is carried out by use of a hydrogen donor such as hydrogen, an acidic trialkylammonium salt, an alcohol or a metal hydride together with a palladium or Ni complex as catalysts.
9. The method according to claim 8, characterized in that the reaction is carried out by use of triethylammonium formate together with PdCl2 (PPh3) 2 as catalyst and bis (diphenylfosfino) propane as cheating agent.
10. A compound having a formula of Compound B as disclosed in Scheme 1, characterized in that the Rgroups have such meanings that said compound is an ester, ether, sulfonyl ester, Oarylisourea, aryl cyanate, aryloxytetrazole or arylbenzoxazole.
11. The compound according to claim 10, characterized in that R is a sulfonyloxy group.
12. The compound according to claim 11, characterized in that the sulfonyloxy group is trifluoromethane sulfonyloxy.
Description:
METHOD FOR THE PREPARATION OF ENTEROLACTONE FROM MATAIRESINOL.

FIELD OF THE INVENTION This invention concerns a method for the synthesis of the mammalian lignan enterolactone from matairesinol.

BACKGROUND OF THE INVENTION The publications and other materials used herein to illuminate the background of the invention, and in particular, cases to provide additional details respecting the practice, are incorporated by reference.

Plant lignans such as matairesinol and secoisolariciresinol, are converted by gut microflora to mammalian lignans, enterolactone and enterodiol, correspondingly (Axelson et al. , Nature, 298: 659-660, 1982).

Enterolactone is known to possess many valuable therapeutical properties.

Urinary excretion and serum concentrations of enterolactone are low in women diagnosed with breast cancer (Ingram et al., Lancet, Oct 4; 350 (9083): 990-994,1997 ; Husten et al. , COST 916 Workshop"Phyto- oestrogens: exposure, bioavailability, health benefits and safety concerns", 1998) suggesting that this lignan is chemopreventive. The inhibition of aromatase by enterolactone would suggest a mechanism by which consumption of lignan-rich plant food might contribute to reduction of <BR> <BR> estrogen-dependent diseases, such as breast cancer (Adlercreutz et al. , J<BR> Steroid Biochem Mol Biol, 44: 147-153,1993 ; Wang et al. , J Steroid Biochem Mol Biol, 50: 205-212,1994). The potential antioxidant activity of enterolactone could also represent a mechanism associated with the preventive action of this lignan in the development of cancers.

The international patent publication WO 00/59946 suggests discloses that hydroxymatairesinol is efficiently converted to enterolactone in vivo and thus useful to increase the level of enterolcatone.

Isolated mammalian lignans such as enterolactone, have, however, not been available earlier in sufficient amounts to be used in animal experiments or clinical trials. The only possibility to increase lignan intake has been to increase the consumption of fiber-rich food items such as flaxseed.

Methods for the synthesis of enterolactone have been disclosed earlier e. g. by MB Groen and J Leemhuis, Tetrahedron Letters 21,5043 (1980) and G Cooley et al. , ibid 22, 349 (1981). The known methods are, however, total syntheses and include at least six steps.

The aim of the present invention is to provide a novel method for the synthesis of large amounts of enterolactone from a plant lignan, which in turn also can be produced in large amounts.

SUMMARY OF THE INVENTION This invention concerns a method for the preparation of enterolactone. The method comprises the steps of a) transformation of the phenolic hydroxyl groups of matairesinol to groups R, which are removable by hydrogenolysis, to give Compound B in Scheme 1, b) substitution of the groups R in Compound B in Scheme 1 with hydrogen, to give bis-3, 3'-O-methylenterolactone, and c) conversion of the methoxy groups in bis-3, 3'-O-methylenterolactone to hydroxyl groups.

DETAILED DESCRIPTION OF THE INVENTION The transformation of the phenolic hydroxyl groups in matairesinol (Compound A in Scheme 1) is preferably carried out by reactions leading to derivatives such as esters, ethers, sulfonyl esters, O-arylisoureas, aryl cyanates and aryloxytetrazoles or-benzoxazoles (Compound B in Scheme 1).

Preferable reagents are anhydrides or halides of carboxylic acids, phosphoric acids or sulfonic acids as well as carbodiimides, cyanogen bromide, chlorotetrazoles and chlorobenzoxazoles. Particularly preferable are sulfonic acid anhydrides such as triflic acid anhydride.

Compound B in Scheme 1 represents a novel group of compounds.

The substitution of the groups R in Compound B in Scheme 1 with hydrogen atoms by hydrogenolysis is preferably carried out by catalytic hydrogen transfer (homo-or heterogenous conditions) using a hydrogen donor and palladium or Ni complexes, palladium metal on a carrier such as carbon, platinum oxides or Raney-type catalysts such as Raney-Ni. In many cases the hydrogenolysis can be achieved by catalytic hydrogenation. Preferable reagents are hydrogen donors such as acidic trialkylammonium salts, alcohols or metal hydrides together with palladium or Ni complexes as catalysts.

Particularly preferable is triethylammonium formate together with PdCl2 (PPh3) 2 as catalyst and bis (diphenylfosfino) propane as chelating agent.

The resulting compound, bis-3, 3'-O-methylenterolactone (Compound C in Scheme 1) has been disclosed previously. Its demethylation to enterolactone (Compound D in Scheme 1) has also been described earlier (Sibi, P. M. , Liu,<BR> P. and Johnson, M. D. , Can J. Chem, 2000, 78, 133; Yoda, H. , Kitayama, H., Katagira, T. and Takabe K., Tetrahedron, 1992, Vol. 48, No. 16,3313.)

The methoxy groups in bis-3, 3'-O-methylenterolactone can be converted to hydroxyl groups by several different ether cleavage reactions. Preferably the reaction is carried out by use of Lewis acids, such as boron or aluminium halides, strong mineral acids such as HBr or HI, or metal hydrides, halides, amides, cyanides or sulfides, or silyl halides and silanes. A particularly preferable reagent is BBr3. Suitable solvents are ethers such as diethyl ether or tetrahydrofuran or halogenated hydrocarbons such as dichloromethane.

According to a preferable alternative, the matairesinol used as starting material is prepared by catalytic hydrogenolysis of the 7-OH-group in hydroxymatairesinol. A method for the preparation of matairesinol from hydroxymatairesinol by use of palladium in acetic acid ester was described by Freudenberg K and Knof L,"Lignanes des Fichtenholzes". Chem. Ber. 90, 2857-69, 1957. According to novel studies, the method can be essentially improved by using pressurized catalytic hydrogenolysis.

Hydroxymatairesinol can, in turn, be produced in large amounts from wood.

It has recently been found that high amounts of hydroxymatairesinol can be produced by extracting finely divided wood material, preferably spruce knotwood, with a polar solvent or solvent mixture and precipitating hydroxymatairesinol from the extract as a complex. Suitable solvents to be used in the extraction step are, for example, pure ethanol or a mixture of ethanol and ethyl acetate. After the extraction step at least part of the solvent is preferably withdrawn before the addition of a complexing agent, which preferable is a carboxylate, such as acetate, of an alkali metal, such as potassium, an earth alkali metal, or ammonium. Such carboxylates form crystallisable adducts with hydroxymatairesinol. An especially preferable complexing agent is potassium acetate, which gives an easily crystallisable

potassium acetate adduct of hydroxymatairesinol. This adduct can easily be used as such in the catalytic hydrogenolysis to matairesinol.

The invention is described in more detail by the following non-restrictive Examples.

EXAMPLE 1 To 1.076 g (3 mmol) of matairesinol (A, see Scheme 1), 2.6 g lutidine and 15 ml of dry dichloromethane were added. The reaction mixture was cooled on an icebath. Under argon 1.2 ml (7.2 mmol) of triflic anhydride was added slowly through a septum. After 68 hours the reaction was ended. 200 ml of dichloromethane was added and the mixture was extracted *5 with distilled water. The organic phase was dried over Na2S04, filtered and the solvent was removed with a rotary evaporator. The product was purified by flash chromatography, (ethylacetate: petoleum ether, 1: 3), and 1.640g (88%) of pure 4, 4'-bis-O-trifluoromethane sulfonylmatairesinol (a compound of formula B in Scheme 1) was obtained.

4, 4-Bis-O-trifluoromethanesulfonylmatairesinol : HRMS m/z calculated for C22H20F601oS2 (M+) 622.0402 found 622.0403.

'H NMR (500 MHz, CDC13) 8 2.48 (1H, m, H-8'), 2.62 (1H, d J =8. 7,6. 0 Hz, H-8), 2.69 (1H, dd J=13. 4,7. 3 Hz, H-7'), 2.70 (1H, dd J=13. 6,7. 0 Hz, H-7'), 2.99 (1H, d J=6. 7 Hz, H-7), 3.85 (1H, s, CH3-O'), 3.86 (1H, s, CH3-O), 3.92 (1 H, dd J =9. 1,7. 9 Hz, H-9'), 4.23 (1 H, dd J =9. 1,7. 5 Hz, H- 9'), 6.60 (2H, dd J=8. 2,2. 1 Hz, H-6, H-6'), 6.64 (1H, d J=2. 0 Hz, H-2'), 6.85 (1H, dJ=2. 0 Hz, H-2), 7.11 (1H, dJ=8. 2 Hz, H-5'), 7.13 (1H, dJ =8.2 Hz, H-5). 13C NMR (500 MHz, CDCl3) 8 34.53, 38.49, 40.87, 46.40,

55. 18 (CH3-0'), 55.26 (CH3-O), 70.96 (C-9'), 113.37, 114.04, 117.47, 118.75 (q, J =332. 1 Hz, CF3), 120. 13, 120. 64, 121. 39, 122.46, 122. 82, 139.28, 139. 42, 151.62 (2C), 177. 81 (C-9).

EXAMPLE 2 0.622 g (1 mmol) of 4, 4'-bis-O-trifluoromethanesulfonylmatairesinol was dissolved in 3 ml of DMF and 0.6 ml triethylamine was added. To the reaction mixture, stirred under argon at 85°C was added 62 mg (0.15 mmol) of 1, 3-bis (diphenylphosphino) propane and 37 mg (0.06 mmol) PdC12 (PPh3) 2.

Finally formic acid (6 drops) was added. The reaction was ended after 25 hours. 50 ml dichloromethane and 50 ml dist. water were addded. The organic phase was washed with 6 * 30 ml 10% HCl solution, 30 ml Brine and dried over Na2S04, filtered and finally the solvent was removed under reduced pressure. The reaction mixture was filtered though a 3 cm layer of silica, and gave 0.73 mmol, 0.237 g (73%) of bis-3, 3'-O-methylenterolactone (C) in 90% purity.

EXAMPLE 3 80 % pure C (estim. 0.67 mmol) was dissolved in 3 ml of dichloromethane, the reaction mixture was cooled to-79°C before 1.6 ml of 1M BBr3 in diethyl ether was slowly added. After 2 hours of reaction at-78°C the mixture was allowed to warm to room temperature over night. The following day the mixture was cooled again and 1 ml of methanol was added. Later 30 ml of NaHC03 solution and 50 ml ethylacetate were added. The pH value was adjusted to 6-7 with dilute HC1 solution, and the organic phase was washed with brine (2 *50 ml) and finally dried over NagS04.

The demethylation was successful and after the reaction no C could be found.

According to GC analysis the yield of enterolactone was 60%.

It will be appreciated that the methods of the present invention can be incorporated in the form of a variety of embodiments, only a few of which are disclosed herein. It will be apparent for the expert skilled in the field that other embodiments exist and do not depart from the spirit of the invention.

Thus, the described embodiments are illustrative and should not be construed as restrictive.

SCHEME 1